A new board game called Legless in London, based on research completed at Swansea University, which brings disability culture ...

The Royal Society of Chemistry has announced that a Swansea researcher is one of the winners of its 2025 prizes in Research and Innovation, which celebrate exceptional people advancing the chemical ...

This marks consistent growth over the past five years, with Swansea advancing 182 places since 2021, when it was ranked 474 th. The global league table by higher education analyst QS Quacquarelli ...

Applying for Postgraduate study at Swansea University? Whether you are preparing to apply for postgraduate study, have already applied for your postgraduate course, have received your offer of a place ...

As part of the Restoration Ecology And Dynamics (READY) Doctoral Focal Award, we invite applications to the following PhD project: Harnessing ecosystem resilience to inform woodland restoration across ...

Summer programmes open to nursing and physician associate students Due to the setup of nursing, midwifery and physician associate timetables, students on these programmes have the option of applying ...

Salary: £39,355 to £45,413 per annum Closing Date: 29-06-2025 Job Number: SU00971 ...

Professor Iain Whitaker holds the Chair of Plastic Surgery in Swansea University Medical School and is also honorary consultant plastic surgeon at the Welsh Centre for Burns and Plastic Surgery at ...

The average diagnostic delay - time from first lupus symptoms to lupus diagnosis - among study participants was 7.5 years, with one patient having to wait 40 years. Participants diagnosed in more ...

The Wales Institute of Social and Economic Research and Data (WISERD) has secured £1.6m of funding from the UKRI Economic and Social Research Council (ESRC) for the three-year research programme, ...

Professor Maurice Whitehead, emeritus professor of history, has recently completed ten years as Director of Heritage Collections and Research Fellow at the Venerable English College in Rome. Founded ...

The SOUL trial, sponsored by Novo Nordisk, was a multicentre, international, randomised, double-blind, parallel-group, placebo-controlled, phase 3 cardiovascular outcomes trial with 9,650 people ...